Shufeimin

Shufeimin (azelastine hydrochloride and fluticasone propionate nasal spray) is a fixed-dose combination nasal spray developed by Changfeng Pharmaceutical for the treatment of moderate-to-severe allergic rhinitis. It combines azelastine hydrochloride, a histamine H1 receptor antagonist, and fluticasone propionate, a glucocorticoid receptor agonist, in a single intranasal formulation. This combination provides rapid and effective relief of both nasal and ocular symptoms by targeting both the early- and late-phase allergic responses. Shufeimin was approved in China in November 2022, representing the first nasal corticosteroid-antihistamine combination spray approved in the country, and was subsequently included in the National Reimbursement Drug List (NRDL) in 2023.

Brand names

ShuFieMinShufeimin

Other names

AzeFluazelastine hydrochloride and fluticasone propionate nasal spray氮䓬斯汀氟替卡松鼻喷雾剂